NEJM· @NEJM · X·· 17 天前精选AI 评分58
AI 导读
NEJM以Quick Take视频汇总了tozorakimab治疗COPD的研究结果,该药是抑制IL-33活性的单克隆抗体。两项2期试验评估了在维持治疗基础上加用tozorakimab,3期OBERON与TITANIA试验的研究发现也在视频中一并总结。
推荐理由
两项2期试验与OBERON、TITANIA两项3期研究共同指向IL-33单抗在COPD维持治疗基础上的加用价值。
正文
COPD can be associated with exacerbations despite maintenance therapy. Two phase 2 trials tested add-on tozorakimab, a monoclonal antibody that inhibits interleukin-33 activity. Research findings from the phase 3 OBERON and TITANIA trials are summarized in a new Quick Take video. https://nej.md/47Edhqp
来源:NEJM · x.com